GlassScriptPhysician profile
Amanda C Garr
NPI 1609218304
$5,493.19
in general payments reported to CMS, 2019-2025
23 companies · $618 in 2025
The $618 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,453 · 2022: $1,087 · 2023: $1,311 · 2024: $1,024 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,714 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,713.50 |
| Education | $240.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,228.80 | 2021-2025 | Caplyta |
| Alkermes, INC. | $770.28 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $733.76 | 2021-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Teva Pharmaceuticals USA, INC. | $692.56 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Abbvie INC. | $664.48 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $199.13 | 2021-2023 | Trintellix |
| Axsome Therapeutics, INC. | $186.18 | 2022-2024 | Sunosi, Auvelity |
| Janssen Pharmaceuticals, INC | $162.40 | 2021-2023 | Invega Sustenna, Invega Trinza |
| Vanda Pharmaceuticals INC. | $95.91 | 2021-2024 | Fanapt |
| Corium, LLC | $89.33 | 2022-2025 | Azstarys |
| Indivior INC. | $84.45 | 2022-2023 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $81.73 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $73.46 | 2021 | |
| Neurocrine Biosciences, INC. | $68.36 | 2022-2023 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $61.48 | 2021-2024 | Qelbree |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $54.70 | 2022-2023 | Jornay Pm |
| Eisai INC. | $54.14 | 2021 | |
| Idorsia Pharmaceuticals US INC | $53.66 | 2022-2023 | Quviviq |
| Lundbeck LLC | $45.04 | 2022 | |
| Merck Sharp & Dohme LLC | $29.77 | 2021 | |
| Biogen, INC. | $23.69 | 2021 | |
| Avanir Pharmaceuticals, INC. | $20.01 | 2022 | |
| Jazz Pharmaceuticals INC. | $19.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Garr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.